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ABSTRACT
Treatment resistance in schizophrenia is a fairly common problem faced by psychiatrists worldwide. The concept and definition of
Treatment Resistant Schizophrenia (TRS) is still far from satisfactory. Data suggests the presence of biological factors underlying TRS.
Second generation antipsychotics are advocated for patients with TRS. However, till date, clozapine remains the treatment of choice.
Evidence for other pharmacological measures and ECT is accumulating. Psychosocial interventions do form an integral component of
management of TRS. It can be concluded that, with advances in psychopharmacology, TRS needs to be better researched and managed
in the future.
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Introduction
One fifth to one third of all patients with schizophrenia are
resistant to drug treatment (Conley and Kelly, 2001).
Management of such patients remains a persistent public
health problem. Patients with Treatment Resistant
Schizophrenia (TRS) are found highly symptomatic, require
extensive periods of hospitalisation, and comprise a high
share of total cost towards treating schizophrenia
(McGlashan, 1988; Revicki et al, 1990). Newer
antipsychotics, especially after proven efficacy of clozapine
in TRS, has given hope for such patients.
TRS: EVOLUTION OF CONCEPT
Patients with schizophrenia are not homogenous due to
differing diagnostic criteria, etiopathogenesis,
symptomatology, stage of illness and comorbid pathology.
Similarly there is marked heterogeneity of response to
treatment in different studies depending on the diagnostic
and inclusion criteria, target symptoms, and pharmacological
and psychosocial treatment applied. Therefore, treatment
resistance in schizophrenia is difficult to define and criteria
still remain controversial.
Initially, chronic hospitalisation (hospitalisation more than
two years) was taken as the criteria for treatment resistance
(Small et al, 1975; Carman et al, 1981). This approach did
not prove to be of help because a person may be hospitalised
for various other reasons like poor compliance or inadequate
psychosocial support, despite having low symptomatology.
 Later, considering the good response of positive symptoms
to typical antipsychotics, persistent positive symptoms
despite adequate drug therapy became the criterion for
treatment resistance in schizophrenia. Kane and co workers,
in 1988 during their Multicenter Clozapine Trial, used the
same concept of Treatment Resistant Schizophrenia (TRS).
Their approach however underestimates the importance
of symptoms other than the positive symptoms of
schizophrenia. Studies are now available which demonstrate
that newer antipsychotics are also effective in improving
negative and cognitive symptoms (Kane, 1999). Henceforth,
it becomes essential that if one wants to assess the treatment
response, it has to be assessed in all domains, and not of
positive symptoms alone.
Kane (1996) while defining  “inadequate treatment
response” in schizophrenia also included patients with
primary negative symptoms, patients who were intolerant
to medication and patients who had  “breakthrough” episode
while on regular medication, other than patients having
persistent positive symptoms.
In clinical settings we do see that treatment response is not
a “yes” or “no” kind of phenomenon and very few patients
suffering from schizophrenia reach their premorbid level.
Considering this, various researchers (May et al, 1988;126
Brenner et al, 1990) took treatment response on a continuum
and gave a dimensional approach to treatment
refractoriness.
“Difficult to treat schizophrenia” is another related concept,
which includes patients who fail to show response not only
to drug therapy but also to psychosocial interventions;
violent, aggressive, non-compliant patients; and patients who
for some reasons evoke negative response from caregivers
including mental health professionals (Kulhara, 1998).
TRS: CRITERIA (Kane et al, 1988)
1. Persistent positive psychotic symptoms: item score > 4
(moderate) on at least 2 of 4 positive symptom items of
the Brief Psychiatric Rating Scale (BPRS) (rated on a
1-7 scale) (Overall and Gorham, 1961)-hallucinatory
behaviour, suspiciousness, unusual thought content, and
conceptual disorganization.
2. Current presence of at least moderately severe illness
as rated by the total BPRS score (>4 on the 18-item
scale) and a score of >4 (moderate) on the Clinical
Global Impression (CGI) scale.
3. Presence of illness: no stable period of good social and/
or occupational functioning within the last 5 years
(inability to maintain work and relationship).
4. Drug-refractory condition: at least 3 periods of treatment
in the preceding 5 years with conventional
antipsychotics (from at least 2 chemical classes) at
doses equivalent to > 1000 mg per day of
chlorpromazine of 6 weeks each, without significant
symptom relief, and failure to improve by at least 20%
in total BPRS score or intolerance to a 6 week
prospective trial of haloperidol at a dose of 10-60 mg
per day.
CRITERIA FOR TRS: CRITIQUE
Categorical Vs Continuum Approach
Full remission from an episode of schizophrenia is unusual
and most patients are at best partial responders (Meltzer,
1990).  Response evaluation will also take into account
whether the persistent symptoms are positive, negative,
cognitive or affective in nature. An alternative, more liberal
definition of treatment refractoriness, proposed by Meltzer
(1990) is the failure of patients to return to their best
premorbid level of functioning. But the disadvantage of this
approach was that all partial responders were considered
equal and further, not qualitatively different from patients
who were completely refractory. Brenner et al (1990)
recommended conceptualisation of a continuum of response
refractoriness to antipsychotic medication. They described
seven levels of response ranging from full clinical remission
to severely refractory. Addressing the controversy between
categorical and continuum approach, Peuskens (1999)
concluded that the dichotomous definition of TRS may be
a useful approach for research. However, it does not fully
appreciate the impact of residual symptoms and
psychosocial problems and will underestimate the number
of partially and poorly responding patients.
Symptom profile in TRS
Resistance to positive symptoms increases over time, in
contrast negative and cognitive symptoms are usually
present from the first episode (Meltzer et al, 1998).
Additionally, impairment in cognitive function contributes
to poor long term outcomes for patients of schizophrenia
(Conley and Kelly, 2001). Drugs shown to be effective in
TRS (clozapine, risperidone) have demonstrated efficacy
in reducing negative and cognitive symptoms, but there is
controversy regarding whether these drugs truly treat
primary negative symptoms or whether their effect is
associated with secondary benefits on depressive,
extrapyramidal, or positive symptoms (Meltzer, 1994;
Lieberman et al, 1994).
TRS: Duration Criteria
Persistence of illness for more than 5 years was taken as
the duration criteria for TRS by Kane et al (1988). This
was most probably the impact of serious side effects of
clozapine (drug induced agranulocytosis), which made
researchers so stringent about duration criteria. On the other
hand clinical history of persistent psychosis for at least 2
years is found to be sufficient for TRS (Brenner et al, 1990).
Even some researchers have mentioned that one year of
unresponsiveness to treatment may be an adequate time
period (Peuskens, 1999).
TRS: Adequate Drug Trial
 The fact that there was only a 3% response rate to
prospective haloperidol treatment and a 4% response rate
to double blind chlorpromazine treatment in the Multicenter
Clozapine Trial led to the belief that failure of two
retrospective drug trials would be as effective as 3 in
screening for treatment resistance (Kane et al, 1988). Kinon
et al (1993) mentioned that subjects who do not respond to
2 adequate antipsychotic trials (1 retrospective and 1
prospective) have less than 7% chance of responding to
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another trial. The FDA guidelines on clozapine use state
that a patient before being treated with clozapine should
have failed to respond to two separate trials of
antipsychotics. Thus, two drug trial failures are generally
accepted as the criterion for treatment resistance.
The evidence that second generation antipsychotics are
somewhat more effective than traditional medications has
opened the question of the type of the drug patient should
fail (Marder, 1996). Most clinicians agree that failure to
respond to second generation antipsychotics should precede
a clozapine trial (Smith and Docherty, 1998). It is generally
recognized that a four to six week period (rather than a
strict 6-week period) is adequate for a treatment trial (Kane
and Marder, 1993).
Recommended dosage ranges have also been revised.
Initially at least 1000 mg per day of chlorpromazine (or its
equivalent) was the proposed dose for use during a
conventional antipsychotic trial. However, doses greater
than or equal to 400 mg of chlorpromazine adequately block
80% to 90% of dopamine receptors (Farde et al, 1992). It
has been additionally reported that higher doses produce
no direct therapeutic benefit even in patients who are
nonresponsive to therapy(Kinon et al, 1993) and do not
improve efficacy in acute treatment (VanPutten et al, 1990).
 Kane et al (1988) in their Multicenter Clozapine Trial
defined treatment response as 20% or more decrease in
total BPRS score, and final score of 36 or less.Conley and
Buchanan (1997) modified the treatment response criteria
as 20% or more decrease in total BPRS and final score of
36 or less or drop on another scale usually to a score
equivalent to mild psychosis. Meltzer (1990) took treatment
responsiveness on a continuum. This seems appropriate
for clinical settings.
TRS: ETIOPATHOGENESIS
Certain neurodevelopmental factors have been found to be
associated  with poor treatment response as shown in
table 1.
If we go by the neurodegenerative pathology of
schizophrenia, it has been found that some patients worsen
over the course of the illness either because of its
progression or because they become less responsive to
treatment (Wyatt, 1991).
Similarly,duration of untreated psychosis was found to be a
strong predictor of future relapse, longer course and
incomplete recovery in patients with schizophrenia (Crow
et al, 1986). Miller and Chouinard (1993) proposed loss of
cholinergic neurons as a  cause for treatment resistance in
schizophrenia. It was found that conventional antipsychotics
acting at D2 receptors produce their therapeutic effect
indirectly by action on the cholinergic interneurons, followed
by reduction of firing of dopamine neurons themselves. This
in turn reduces the dopaminergic activation of D1 receptors.
Loss of cholinergic interneurons prevents standard
neuroleptic drugs from having their therapeutic effect. On
the other hand, drugs acting by blocking the D1 receptors
e.g. clozapine should still be able to exert a direct effect
and improve the so-called ‘drug resistant positive
symptoms’.
TRS: EPIDEMIOLOGY
In early antipsychotic trials (Cole et al, 1966; Klein and
Devis, 1968) approximately 30% of schizophrenic patients
derived little, if any, benefit from medication. Clinical trials
done in 1990’s (Levinson et al, 1990; McEvoy et al, 1991;
Kinon et al; 1993) showed that only 50% of patients showed
a good response to conventional antipsychotics. This raises
the question whether response to medication has declined
over past three decades. Kane et al (1996) proposed that
change in nosology with a tendency to overdiagnose
schizophrenia and underdiagnose affective illness in 1960’s,
increasing prevalence of substance abuse among patients
and current policy of limited hospitalisation could be some
of the reasons for this trend. Hegarty et al (1994) conducted
a meta- analysis of 20th century literature on outcome of
schizophrenia and concluded that despite widespread use
of neuroleptic drugs and other contemporary treatments, a
shift had occurred towards poorer outcome in the last
decade.
TABLE 1 :
Neurodevelopment factor and
poor treatment response
Factor(s) Author
Lower level of premorbid Murray et al, 1992
functioning, presence of
deficit state, male gender,
cavum septum pellucidum
High prevalence of Weinberger, 1995
obstetrical complication
Lateral and third ventricle Lieberman et al, 1993
enlargement
Vulnerability to tardive Chakos et al, 1996
dyskinesia
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Prevalence of TRS: Clozapine Related Studies
 One strategy for examining the epidemiology of treatment
resistance in schizophrenia is to apply the eligibility criteria
for clozapine treatment to specific populations. Till date three
studies were available (Table 2).
MANAGEMENT OF TRS
TRS: DRUG THERAPY
(a) Conventional Antipsychotics
A number of studies have examined the effect of high dose
typical antipsychotics in patients who are poor or partial
responders but found little conclusive advantage (Quitkin
et al, 1975). In controlled trials in patients with drug-resistant
symptoms, fewer than 5% responded after therapy was
changed from one conventional antipsychotic to another
(Kane et al, 1988; Breier et al, 1993). Kinon et al (1993)
found that there is no advantage of increasing the dose,
changing to another medicine or prolonging treatment. On
the other hand, Shalev et al (1993) observed further
improvement with specific alternatives of prior conventional
antipsychotic treatment administered over a period of time
longer than 4 to 8 weeks.
(b) Second Generation Antipsychotics
CLOZAPINE
Though some anecdotal reports and clinical trials (Claghorn
et al, 1987) had suggested that clozapine might be effective
in TRS, the most definitive evidence of its effectiveness
came from a multicenter trial (Kane et al, 1988) in which
clozapine was compared with chlorpromazine. Thirty
percent of clozapine patients met improvement criteria (as
compared to 4% chlorpromazine treated patients) after a 6
week trial. Breier et al (1993) and Schooler et al (1997)
indicate that higher proportion of TRS patients (up to 60%)
will meet stringent improvement criteria if the trial period is
extended to a longer period (up to 29 weeks). It has been
suggested that clozapine may be helpful in a broader
population of TRS patients, including patients living in the
community (Schooler et al, 1997). As per current
understanding, clozapine is the only drug with proven
efficacy in rigorously defined TRS and undoubtedly superior
to coventiontional antipsychotics in this population (Chakos
et al, 2001). On the other hand, in a recent meta-analysis,
Moncrieff (2003) addressed the issue of heterogenicity in
clozapine related study and found that recent large studies
have not found a clinically relevant advantage for clozapine.
Meta-regression showed that shorter study duration,
financial support from a drug company and higher baseline
symptom score consistently predicted greater advantage
of clozapine. Females, patients having higher mean
metabolic ratio, and lesser fall in total white cells and
neutrophils after institution of clozapine were found the
good predictor of response (Mauri et al, 2003). Temporal
grey matter volume and metabolism, metabolic activity in
thalamus, pallidium/putamen and caudate nucleus correlated
with improvement in positive symptoms, whereas patients
with high baseline dorsolateral prefrontal volume and
metabolic activity were more likely to experience
improvement in negative symptoms. Improvement in
disorganised symptoms was inversely correlated to total
intracranial volume and hippocampal volume (Molina et
al,2003). Significantly more number of patients with
cognitive disorganisation were found among nonresponders
and patients with behavioural disorganisation were found
more among partial responders to clozapine (Rodriguez et
TABLE 2 :
Prevalence of TRS
Study Prevalence of
treatment Remarks
resistance in patients
with schizophrenia
Terkelsen and Grosser (1990) 18% of inpatients More stringent criteria than current FDA guidelines.
25% of outpatients No assessment for adequacy of prior
medications trial
Juarez-Reyes et al (1995) 43% (n=293) Patients of tardive dyskinesia were also included.
Essock et al (1996) 60% (n=1300) Extrapolated from their data that on any given
day in US country and state hospitals
approximately 40,000 patients would meet
eligibility criteria for clozapine
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al, 1998). Improvement with clozapine is mainly
documented in positive symptoms, affective symptoms,
suicidal behaviour and frequent hospitalisations (Schatzberg
et al, 2003).
RISPERIDONE
There were early reports of (Chouinard et al 1994; Keck
et al 1995) some response with risperidone but these studies
were open label, retrospective, or not controlled. Risperidone
has also been found to have favourable effect on ability to
accurately perceive emotions and verbal working memory
in patients with TRS (Green et al, 1997; Kee et al, 1998).
A well controlled, double blind study by Wirshing et al (1999)
showed that risperidone is more effective and better
tolerated than haloperidol in TRS. Risperidone showed
similar efficacy to clozapine in a few studies (Klieser et al,
1995; Bondolfi et al, 1998) but TRS criteria were poorly
defined and the sample size was small. Clozapine was found
to have superior efficacy than risperidone (Azorin et al,
2001) and risperidone treatment was not found to be
effective in clozapine responders (Lacey et al, 1995; Shore,
1995).
OLANZAPINE
There have been several open reports of possible efficacy
with olanzapine in treatment resistant patients (Martin et
al, 1997; Thomas and Labbate, 1998; Dossenbach et al,
2000) but the inclusion of less stringently defined patient
population in some of these studies has been of concern.
Double blind and open label studies show that olanzapine is
more effective than conventional antipsychotics, but it is
not as effective as clozapine (Conley et al, 1998; Sanders
and Mossman, 1999; Breier and Hamilton, 1999).
Furthermore, olanzapine resistant patients respond to
subsequent trial of clozapine at about the rate that would
have been expected in any other treatment resistant group
(Conley et al, 1999).
OTHER SECOND GENERATION ANTIPSYCHOTICS
Studies on efficacy of other second-generation
antipsychotics in TRS are lacking. Quetiapine has been
found beneficial in partially responding patients with
schizophrenia (Emsley et al, 2000). However no controlled
trials in strictly defined TRS patients have been published.
Recently, Chakos et al (2001) conducted a meta-analysis
based on 12 controlled studies in patients with TRS. Results
indicated that clozapine exhibited superiority over typical
antipsychotics in terms of both efficacy and safety with a
moderate (0.48) effect size, clozapine treated patients are
2.45 times and olanzapine treated patients are 1.71 times
more likely to meet categorical response criteria as
compared to typical antipsychotics, fewer extra pyramidal
side effects with clozapine and olanzapine, and study
completion rate was maximum for risperidone (84.8%),
followed by clozapine (69.6%) and least for typical
antipsychotics (56.1%).
(c) Alternate (adjunct) therapies
If patients remain resistant to treatment after a clozapine
trial or cannot take clozapine, alternate therapies should be
considered (Miller et al, 1999).
LITHIUM
Adjunct lithium therapy was found beneficial in some
patients with TRS (Small et al, 1975; Carman et al, 1981).
A 4-week trial is adequate to determine response. Response
was more prominent in patients with affective symptoms
(Delva and Letemendia, 1986). There are reports that
lithium reduces violent behaviour in TRS patients (Christison
et al, 1991). Published trials of adjunct lithium therapy, though
positive, have been conducted with small number of patients
and the criteria used for defining TRS are not clear or over
inclusive (Kane, 1996). More recent reports have found no
benefit with adjunct lithium therapy (Schulz et al, 1999).
Therefore, definitive evidence on the benefit of lithium is
yet not present. Lithium should be used with caution in
combination with clozapine and other antipsychotics because
of the increased risk of neurotoxicity including delirium
(Barnes and McEvedy, 1996; Small et al, 2003). A relatively
low dosages of lithium (300-900 mg/day) as adjunct is
recommended (Jones and Thompson, 1995).
ANTICONVULSANTS
Controlled trials with adjunct carbamazepine and valproic
acid in TRS have shown positive results (Schulz et al, 1990;
Wassef et al, 2000). However these trials enrolled fewer
subjects, the positive effects noted were modest and usually
involved non-specific improvement in areas such as
behaviour and social adjustment. A meta-analysis done by
Leucht et al (2002) concluded that carbamazepine, as an
augmentation strategy in schizophrenia cannot be
recommended for routine use except for patients with
excitement and aggression. Carbamazepine should not be
used in combination with clozapine due to increased risk of
agranulocytosis (Conley and Kelly,2001). A few cases of
adjunct use of lamotrigine with clozapine with positive results
in TRS have also been reported (Dursun and Deakin, 2001).
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A review (Hosak and Libiger, 2002) on role of adjunct
antiepileptics in schizophrenia mentions that carbamazepine
is effective in affective symptoms of schizophrenia and
influences violent behaviour in psychotic patients, valproate
treatment leads to a decrease in positive symptoms as well
as hostility and lamotrigine is expected to influence the
positive, negative, affective, and cognitive symptoms of
schizophrenia. Topiramate has also been found to be
effective in TRS as an adjunct, especially in negative
symptoms and clozapine induced weight gain (Dursun and
Devarajan, 2000; Drapalski et al, 2001). In most of the
studies of TRS, anticonvulsants have been used in their
usual antiepileptic dosage (Hosak and Libiger, 2002).
BENZODIAZEPINES
There have been several reports on the use of
benzodizepines in TRS. Results have been mixed with some
double blind studies showing a positive effect (Lingiaerde
et al, 1979; Wolkowitz et al, 1992) whereas other studies
have shown negative results (Ruskin et al, 1979; Pato et al,
1989). Because patients with schizophrenia often have
anxiety and irritability, it is not surprising that benzodizepines
are useful in the treatment of this disorder. A high dose of
adjunct benzodiazepine reduces positive symptoms, anxiety
and agitation (Hosak and Libiger, 2002) and prefrontal cortex
atrophy has been found to predict the positive response of
the benzodiazepine augmentation in TRS (Seeley et al, 2002).
ELECTROCONVULSIVE THERAPY (ECT)
There is little evidence that ECT alone can alter the chronic
symptoms (both positive and negative) of schizophrenia,
but in short-term trials, when added to antipsychotic
medications for TRS, it has demonstrated favourable
response (Conley and Kelly, 2001; Goswami et al, 2003).
Up to 20 bilateral ECTs are given before labelling patient
unresponsive to ECT. Male sex, paranoid type, younger
age, shorter duration of illness and shorter duration of
current episode, less family history and higher pre-treatment
functioning were found among good predictors of response
(Chanpattana et al, 1999). Improvement is found more in
positive symptoms than negative ones but beneficial effect
was short lived and significant proportion of patients relapsed
after two to six months of stoppage of ECT (Sajatovic and
Meltzer, 1993; Kales et al, 1999; Chanapattana et al, 1999).
Very few studies are available on continuation or
maintenance ECT in TRS and found ECT in combination
with antipsychotics more effective in preventing relapse as
compared to ECT or antipsychotic alone (Chanpattana,
2000; Chanpattana et al, 1999). Improvement on
maintenance ECT in  TRS is reported in self injurious
behavior, less hospitalisation and better functioning
(Dean,2000). A literature review by Tharyan (2000) reports
that about 20% patients have improvement with ECT in
combination with clozapine. Combined treatment of
clozapine with ECT appears to be safe and well tolerated
(Kales et al, 1999; Tharyan, 2000). Combination of clozapine
with ECT has been proposed as a promising initiation
therapy in severely disturbed and non-compliant patients
with TRS for rapid treatment response and consequently
improved compliance (James and Gray, 1999).
There is very limited evidence for other augmentation
stretegies i.e. beta blockers, calcium channel blockers ,
reserpine, glycine and d-cycloserine having any role in TRS
and cannot be recommended at present (Hollister and
Trivino, 1999; Conley and Kelly, 2001; Schatzberg et al,
2003).
COMBINED ANTIPSYCHOTIC THERAPY (CAT)
While clinical use of CAT in TRS is growing, little research
is available to support this treatment approach (Stahl, 1999).
The most consistent data so far has come mostly from case
reports and open trial studies. Positive results have been
found in combination of clozapine with risperidone (Raskin
et al, 2000; Taylor et al, 2001), olanzapine (Gupta et al,
1998), pimozide, loxapine and sulpiride (Mowerman and
Siris, 1996; Friedman et al, 1997). There is a report of the
combined use of risperidone and olanzapine with success
(Lerner et al, 2000). There is one well controlled, double
blind study showing a positive effect with adjunctive sulpiride
therapy in clozapine partial responders (Shiloh et al, 1997).
While CAT is rising, there is little controlled work and these
preliminary findings needs to be validated.
Regarding practical guidelines for pharmacotherapy in TRS,
clozapine remains the gold standard for these patients. A
fair and adequate trial (maximum dose up to 900 mg/day
for minimum six months) should be given before moving to
other less effective and partially understood measures. At
next stage another antipsychotic (preferably low dose high
potency typical antipsychotic) or other adjunct (lithium or
other mood stabilizers, benzodiazepines) can be added. ECT
always remains an option for acute exacerbation and
maintenance ECT in combination with clozapine can be
considered at a stage when initial response with ECT is
found to be good and none other treatment seems to work.
If patient does not tolerate clozapine or he does not show
any response to it, then another atypical antipsychotics can
be tried.
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TRS: PSYCHOSOCIAL MANAGEMENT
INDIVIDUAL PSYCHOTHERAPY
Specifically regarding TRS, most studies have been done
on cognitive behaviour therapy (CBT). Garety et al (2000)
in their review of available randomised controlled studies
conclusively remarked that, CBT has significant benefits
in terms of symptom reduction (especially positive
symptoms). The predictors of good outcome are cognitive
flexibility and less negative symptoms, with no role of
intelligence and severity of psychotic symptoms, and the
benefits are sustained up to 1-year post treatment follow-
up.
Other than CBT, supportive psychotherapy in the form of
a supportive relationship that consists of friendship, advice,
practical help in securing financial and supportive services,
and vocational counselling has been advised for these
medication resistant patients (Torrey, 1986).
Rosberg and Stunden (1990) argued that patients with
schizophrenia are often labelled treatment resistant because
the psychological treatment they receive is seldom
appropriate for their needs. They further said that the main
problem in treating schizophrenia with psychotherapy is not
the treatment resistant patient but the treatment resistant
therapist.
FAMILY INTERVENTIONS
Psycho-educational interventions with families of patients
with schizophrenia have a well-established literature support.
Behavioural family management is effective in reducing
relapses and readmission rates (Leff et al, 1989, 1990).
Family interventions reduce burden of care, improve
patient’s functioning in social areas and are cost-effective
(Falloon et al, 1982, 1985; Tarrier et al, 1988, 89, 91, 94).
McFarlen et al (1995) and Telles et al (1995) have shown
beneficial effects of family interventions in managing
treatment resistant patients in the community setting.
COMMUNITY BASED INTERVENTIONS
The broad aim of community-based interventions in TRS is
to improve quality of life, stabilize mental health, and
minimize relapses and rehospitalizations. Programs included
for such patients are  “Early symptoms and signs monitoring”
so as to recognize early symptoms of relapse (Birchwood
and Shepherd, 1992), “Assertive Outreach Programme” -
a staff intensive programme aimed at delivery of services
in an aggressive and assertive manner (Wykes and Carson,
1996) and crisis intervention which can reduce
rehospitalizations and benefit the patient clinically and
socially (Muijen et al, 1992).
Conclusion
Treatment resistance in schizophrenia is a concept that still
holds different positions in clinical settings and in research
areas. While categorical and criteria based approach with
more emphasis on positive symptoms is preferred for
research, individualised and holistic view for treatment
resistance seems appropriate for day to day clinical
situations. Regarding pharmacological treatment of TRS,
till now only clozapine has demonstrated conclusive and
favourable evidence. Other second-generation
antipsychotics and adjunct treatment modalities are
promising areas but require large sample studies with good
methodological framework so as to establish their efficacy.
Non- pharmacological interventions, including individual and
family therapies, should not be underestimated or
underemphasized and should be used to their maximal
potential in this special patient population.
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